CorticalBrain.com
Home | NeuroAnatomy| Genetics| Neurology | Psychiatry| Psychology | Evolution | Functional Brain Mapping | Mail | Contact Us

Drug transport across the BBB

Introduction:

The tight junction complex that connects brain microvascular endothelial cells in the BBB as well as the epithelial cells of the choroid plexus that form the blood-cerebral spinal fluid barrier (BCSFB) serve as a physical barrier preventing the paracellular diffusion of endogenous and exogenous compounds. The presence of these tight junctions is essential for maintaining the proper environment required for neuronal transmission. However, paracellular diffusion of nutrients and metabolites between the blood and the extracellular compartment of the brain is also highly restricted. Consequently, the uptake of essential molecules, such as glucose and amino acids, to meet the metabolic requirements of the brain occurs through specific trans‐ porter proteins located on the plasma membrane of the endothelial cells. In addition to transporters that facilitate the entry of various solutes into the brain, the brain endothelial cells also express numerous efflux transporters [71]. These transporters are members of the ATP-binding cassette (ABC) protein family and utilize energy from adenosine triphosphate (ATP) hydrolysis to actively remove compounds from the cells against a concentration gradient.

From a drug transport perspective, there are several transporters that are critically involved in the movements of drugs across the BBB. These include organic anion-transporting poly‐ peptide 1A2 (OATP1A2/SLO1A2), organic anion transporter 3 (OAT3/SLC22A8), monocar‐ boxylate transporter 1 (MCT1/SLC16A1), from the solute transporter family, and P-glycoprotein (P-gp; MDR1/ABCB1), breast-cancer-resistance protein (BCRP/ABCG2) and multidrug-resistance-associated proteins 1-9(MRP1-9/ABCC1-9) from the ABC transporter family [72]. The localization of these transporters in both the BBB and BCSF barrier are shown in Figure 3 with each individual transporter is being discussed in greater detail below.

Organic Anion Transporting Polypeptide (OATP)

Organic anion transporting polypeptides (OATPs) are members of the solute carrier organic anion transporter family (SLCO) [73]. The OATPs accommodate the transport of a wide variety of amphipathic solutes, including bile salts, anionic peptides, steroid conjugates, thyroid hormones and an increasing number of pharmaceutical drugs and xenobiotics [74]. Members of the OATP family, of which there are currently 11 known to be expressed in humans


The-localization-of-transporters

The localization of transporters in the blood brain barrier (BBB) and blood cerebral spinal fluid barrier (BCSFB) of CNS.

(OATP1A2, 1B1, 1B3, 1C1, 2A1, 2B1, 3A1, 4A1, 4C1, 5A1, and 6A1), share a great deal of amino acid sequence identity and transport solutes in a sodium independent manner [75]. Of the various OATPs, both OATP1A2 and OATP1A4 are expressed in the BBB. Organic anion transport protein 1A2 was the first member of the OATP family to be reported in humans, while OATP1A4 is a more recently discovered homolog of hepatic [76]. At the protein level, OATP1A2 (previously designated OATP-A) is expressed in many organs including the liver, intestine, kidney, lung, testes, and the brain. Within the brain, this transporter is localized in the frontal cortex and specifically confined to the endothelial cells of the BBB [74]. Its locali‐ zation on the luminal side of brain microvessel endothelial cells suggests that OATP1A2 aids in the entry of various solutes and therapeutic agents into the brain [74]. While OATP1A4 is mainly concentrated in the liver, the transporter has also been detected within the brain microvessel endothelial cells [74]. In contrast to OATP1A2, immunohistochemical localization studies indicate that OATP1A4 is expressed on both the apical and basolateral side of the endothelial cells of the BBB and thus, mediates the uptake of compounds from both the brain and the blood compartments [77]. Organic Anion Transporter (OAT) Organic anion transporters (OATs) belong to the SLC22A gene family. Similarly to OATPs, the OATs transport a broad range of chemically unrelated endogenous and exogenous compounds. There are at least 10 families of OATs designated by Arabic numbers (eg. OAT1). OAT1 is predominantly expressed in the kidney although a very small amount is also found in the brain particularly concentrated in regions such as cortex, hypothalamus, hippocampus and cerebellum [78]. This transporter is known to interact with a broad range of drugs including antibiotics (penicillins, benzylpenicillin and carbenicillin), antineoplastics (metho‐ trexate) and even cholesterol lowering drugs including the statins and fibrates such as fluvastatin, pravastatin, and bezafibrate, respectively [78]. OAT2, on the other hand, is predominantly expressed in the liver and very little is found in the kidney and brain. The expression level of this transporter in a particular tissue can be influenced by a variety of factors; including gender and species differences [79]. For example, in the adult male rat, the mRNA for OAT2 expression is greater in the liver than the kidney, and the opposite is true for the adult female rat where the mRNA level in the kidney is greater than in the liver [79]. However, this phenomenon has not been observed in humans. Furthermore, the expression level of OAT2 is also influenced by hepatocyte nuclear factors and endogenous gas molecules including nitric oxide [80,81]. Given the similar molecular structure to OAT1, OAT2 also mediates the transport of a broad range of solutes including cholesterol lowering drugs (i.e. statins), antibiotics such as cephalosporins, and antineoplastic drugs like 5-fluorouracil [78]. From a CNS perspective, OAT3 appears to have the greatest expression levels in the brain [78]. Within the CNS, OAT3 is primarily localized in the brain capillaries and in epithelial cells of the choroid plexus, specifically on the basolateral side of the plasma membrane of the cells [82]. The predominantly basolateral localization of OAT3 in the BBB and BCSFB implies that the primary function of OAT3 is to aid in the removal of compounds from the brain. Endogenous products of neurotransmitter and hormone metabolism are potential candidates for OAT3-mediated removal. Potential therapeutic agents that may be transported out of the brain through OAT3-dependent processes at the BBB and BCSFB include the various statins, diuretics, antibiotics and antivirals [78]. As OAT3 interacts with a large number of therapeutic agents, drug-drug interactions may be of potential concern in the BBB, although specific examples are at present not known. Glucose Transporters (GLUT) Glucose is the major source of energy for most mammalian cells, particularly in the brain. Despite the high dependence of the brain on glycolysis, the source of glucose comes entirely from the blood and is dependent on passage through the BBB. The entry of glucose into the brain is mediated by facilitative glucose transporter proteins. There are currently seven known isoforms, with the designation of GLUT1-7 [83]. The main isoforms found within the CNS are GLUT1 and GLUT3 that bring glucose into the cell through sodium independent transport mechanisms. A summary of the various GLUTs and their distribution within the CNS is shown in Figure 4. GLUT1 within the CNS exists as two distinct forms, which differ only by the extent of glycosylation [84]. A glycosylated, 55 KDa GLUT1 is found primarily in the endothelial cells of the BBB while the non-vascular, non-glycosylated 45 KDa form is mainly found in neural cells as well as the basolateral plasma of epithelial cells isolated from the choroid plexus [83]. Aside from the prominent expression found in the microvessels and choroid plexus, GLUT1 has also been detected in small cells with dark stained nuclei characteristic of glia cells [85]. Immunohistochemistry staining also showed a positive detection of GLUT1 in astrocytes that are in direct contact with the cerebral microvessels of rat brain slices. Electron microscopy also revealed dense distribution of GLUT1 within the astrocyte foot processes surrounding the microvessels of the gray matter and synaptic contacts [86].
Cellular-localization-of-different-isoforms-of-glucose-transporter

Cellular localization of different isoforms of glucose transporter in the CNS

The main glucose transporter in the BBB is GLUT1. This same transporter is also highly expressed in the blood-retinal barrier, the placental barrier, and blood-CSF barrier (BCSFB) [87-89] highlighting its importance in regulation of glucose levels in these tissues. The transport of glucose through GLUT1 in the BBB is the rate-limiting step for glucose utilization in the brain and is highly responsive to metabolic changes within the brain. For example, GLUT1 expression in the BBB at both the mRNA and protein level can increase or decrease depending on the ambient concentration of hexose. High concentration of hexose decreases the expression of GLUT1 while low hexose concentration causes an up-regulation of both GLUT1 mRNA and protein levels [90]. Following brain injury such as a stroke and brain tumors, both mRNA and protein levels of GLUT1 are significantly increased [83,85,91]. The endothelial cells forming the BBB also express sodium glucose cotransporter (SGLT) [92]. Unlike GLUT1, glucose transport through SGLT is sodium-dependent. A functional role for SGLT in glucose homeostasis in the brain has not been established; however, it has been speculated that SGLT may help maintain intracellular glucose levels in the brain under stressful conditions such as hypoglycemia [92]. 6.4. Monocarboxylate Transporter (MCT) Monocarboxylic acids, including lactate, pyruvate, and ketones play an important role in energy metabolism within the body. Monocarboxylates such as pyruvate, lactate, and ketone bodies (i.e acetoacetate and β-hydroxybutyarate) can be utilized by neurons, in the absence of glucose, to generate a substantial amount of energy for the brain [93]. Under pathological and physiological conditions including diabetes, prolonged starvation, hypoglycemia, or even intense exercise, the build-up of lactate provides an energy source, which can be utilized by the brain [3,94,95]. In addition, monocarboxylates including lactic acid are a metabolic by-product produced and released within the CNS by neurons [96,97], astrocytes [96] and oligodendrocytes [98]. As monocarboxylates are hydrophilic compounds that cannot readily diffuse cross the BBB, specific transporter systems are required to maintain proper levels of these endogenous metabolic products in the brain [93]. Sequence homology indicates that the monocarboxylate transporter family (previous known as SLC16 gene family) consists of 14 members identified as MCT1-9, MCT11-14 and T-type amino acid transporter 1 (TAT1) [99]. MCT1-4 is a symporter mediating the co-transport of monocarboxylate and proton in a one to one stoichiometry ratio. MCT1-4 is present in almost all tissues including the muscles, liver, kidney, heart, testes, and brain [93,99]. While MCT1 and MCT2 are found in the muscles, liver, kidney, heart and CNS, [93], MCT3 is exclusively expressed on the basolateral side of the retinal pigment epithelium and MCT4 is highly expressed in the skeletal muscles and also in the brain. Within the BBB, MCT1 was the first monocarboxylic acid transporter identified in the brain microvessel endothelial cells and in the ependycytes lining the ventricles [100]. Both electron microscopy and immunohistochem‐ istry revealed a small amount of MCT1 in astrocytic end-feet surrounding the capillaries [100,101]. The presence of MCT1 was found in the cytoplasm of astrocyte and also associated with the plasma membrane [93]. In contrast, MCT2 is found in endothelial cells forming the BBB, but absent in astrocytes [93,100]. MCT4, on the other hand, was exclusively expressed in the astrocytes and glial cells of rodent brain. Furthermore, when the hippocampus and the corpus callosum were labeled, the expression of MCT4 was restricted to astrocytes [93]. MCT8 was recently recognized as thyroid hormone transporter as opposed to monocarboxylate [102]. 6.5. ATP-Binding Cassette Transporters (ABC) The ATP-binding cassette (ABC) superfamily of transporter proteins are responsible for the active transport of a wide variety of compounds including phospholipids, ions, peptides, steroids, polysaccharides, amino acids, organic anions, bile acids, drugs and other xenobiotic compounds across cellular membranes. There are roughly 48 genes encoding the various human ABC transporters, each is organized into seven subfamilies designated ABCA to ABCG [103]. Over-expression of ABC transporters are major contributors to the development of multidrug resistance (MDR) in cancer cells. For instance, when the MDR gene that codes for an efflux transporter is being transfected into drug sensitive cells, the transfectant cells become resistant to the drugs that are substrates for the transporters resulting in a decrease in the intracellular concentration of the drugs, thereby conferring multidrug resistance [104]. MDR in tumor cell lines is often linked to an ATP-dependent decrease in cellular accumulation of drugs namely through p-glycoprotein (p-gp encoded by ABCB1), multidrug resistance proteins (MRP encoded by ABCC), and breast cancer resistance protein (BCRP encoded by ABCG2) drug efflux transporters [105]. In addition to their function as multidrug resistance proteins, these transporters are also expressed in normal tissue such as intestines, liver, kidney and the BBB and BCSFB, suggesting that they also have a protective function in limiting accumulation and distribution and speeding the elimination of xenobiotic compounds which could result in tissue toxicity [106]. Multidrug Resistance Protein (MRP) The multidrug resistance-associated proteins (MRPs) are a subfamily of ABC transporters. There are currently 12 members of this subfamily designated as ABCC1-12. Of the 12, 9 have demonstrated drug efflux transporter function and play an important role in absorption, distribution and elimination of various drugs and metabolites. While all MRPs have the capability to transport amphiphatic organic anions, transport substrates are not limited to anionic species. Examples of this include the transport of nucleotide based analogs by MRP4 and MRP5, efflux of prostaglandins by MRP1, co-transport of neutral or cationic solutes as well as glucoronide drug conjugates by MRP1 and MRP2 [107]. Within the MRPs and other ABC transport proteins there tends to be substantial substrate affinity overlap. This is a fascinating feature considering most members are structurally and functionally distinct from other ABC binding cassette transporters. For example, there is only approximately 15% amino acid sequence homology between MRPs and P-gp [108]. In addition, when comparing amino acid sequence between different members within the MRP subfamily to MRP1, amino acid sequence homology ranges between 33% for MRP8 and 58% for MRP3 [109]. The brain endothelial cells that form the BBB express several different MRP. Collectively the MRP efflux transporters function to restrict the uptake and aid in the elimination of drugs, xenobiotics and endogenous compounds from the brain. Currently, members of the MRP family that have been reported in the BBB include MRP1, 2,4-9. The evidence for the localiza‐ tion and function of each of the MRPs within the BBB are discussed below. MRP1 MRP1 is expressed in primary cultured bovine, murine [110], rat [111] and porcine [112] brain microvessel endothelial cells. While studies by Seetharaman and coworkers [113] suggested up-regulation of MRP1 expression in human culture brain microvessel endothelial cells compared to freshly isolated human brain capillaries, more recent studies support robust expression of MRP1 within the brain capillaries isolated from human brain tissue [114]. Two independent studies reported that MRP1 is localized primarily to the apical (luminal) plasma membrane in brain microvessel endothelial cells [114,115]. This is in contrast to studies by Roberts et al. [116] suggesting MRP1 has a basolateral (abluminal) plasma membrane locali‐ zation in rat brain microvessels. As MRP1 shows high transporter activity for conjugated compounds such as estradiol 17β glucuronides [117], it is interesting to note that Sugiyama and colleagues [118] demonstrated a reduction in elimination of estradiol 17β glucuronide from the brain of Mrp1 knockout mice compared to that observed in the wild-type controls with functional MRP1. These functional studies support the luminal expression of MRP1 and suggest a role in limiting brain exposure to drugs and endogenous solutes. 6.6.2. MRP2 The expression and localization of MRP2 within the BBB is the subject of much debate. Studies by Miller et al. [119] indicated MRP2 was expressed in the luminal plasma membrane of isolated rat brain capillaries. These initial findings were supported by reports of MRP2 expression in both human brain capillaries as well as zebrafish [120,121]. In contrast, no detectable expression of MRP2 was found, at either the mRNA or protein level, in bovine brain microvessel endothelial cells [122,123] or mouse brain microvessel endothelial cells [110,118]. Furthermore, studies examining MRP2 protein expression in isolated human brain capillaries were below detection limits [114,124]. Interestingly, expression of MRP2 in rat brain endothe‐ lial cells was inducible by activation of either pregnane X receptor (PXR) or constitutive androstane receptor (CAR) pathways [125,126]. Functionally, MRP2 mediates the transport of glucuronide and GSH conjugates to a lesser extent than MRP1 [127]. It also actively transports chemotherapeutics such as methotrexate, vinca alkaloids, anthracyclins, antiepileptics such as phenytoin and endogenous agents like leukotriene C4 [107,109,128,129]. Thus if MRP2 is expressed in the BBB, it could have a profound effect on the brain distribution of many therapeutic agents. However, there are few studies showing a significant impact of MRP2 on the BBB permeability. One such study demonstrated an increased accumulation of phenytoin in the brain of Mrp2 deficient rats compared to controls [129]. There is also evidence for MRP2-mediated changes in brain penetration of drugs in epileptic animals. Based on available information, most evidence indicates that MRP2 expression in the BBB is low or below detectable limits and as such has negligible effects on solute and macromolecule distribution into the brain. However, as MRP2 expression appears highly inducible, there is a possibility that MRP2 activity in the BBB could be of importance during pathological events within the CNS. 6.6.3. MRP3 Studies by Zhang et al. [122] identified low and variable expression of MRP3 in bovine brain microvessel endothelial cells. Subsequent proteomics based studies of both mouse [130] and human [131] BBB indicated that MRP3 expression was below detection limits. 6.6.4. MRP4 Evidence supporting a significant functional role for MRP4 in the BBB is perhaps the strongest of all the MRPs. The first evidence of MRP4 expression in the BBB was the studies by Zhang et al. [122] in bovine brain microvessel endothelial cells. Follow-up studies examining the localization of MRP4 suggested both luminal and abluminal presence of the transporter [115]. The expression of MRP4 has since been reported in human, mouse and rat BBB [114,116,132]. Comparison of MRP4 expression in the brains of wild-type and Mrp4 knockout mice confirmed BBB localization as well as expression in the choroid plexus epithelial cells forming the BCSFB [132]. Functionally, MRP4 can transport a wide variety of substrates and is important in the efflux of many nucleotide analog based chemotherapeutics. As with MRP1 and MRP2, MRP4 transports the endogenous substrate leukotriene C4 [133,134]. However, in addition, MRP4 can also transport endogenous nucleotides such as cAMP and cGMP [135]. Common chemo‐ therapeutic purine nucleotide anion analogs that are effluxed by this transporter include bis(pivaloyloxymethyl)-9-[2-(phosphonomethoxy)ethyl]-adenine (PMEA), and active metab‐ olites of 6-mercaptopurine and 6-thioguanine [72,107,136]. Using Mrp4 -/- knockout mice significant increases in topotecan [132] and PMEA [137] accumulation in the brain was observed. 6.6.5. MRP5 and MRP6 Within the BBB, MRP5 is highly expressed, whereas MRP6 is expressed to a lesser extent [122]. Presently their locations within the BBB remain unclear. Previous studies by Zhang et al. [115] found MRP5 protein expression to be primarily in the apical membrane fraction of brain microvessel endothelial cells. These findings were supported by Nies et al. [114]. In contrast, Roberts et al. [116] found low levels of abluminal MRP5 expression when staining in rat brain microvessel endothelial cells. Currently, the location of MRP6 remains to be seen because no specific MRP6 antibody is available at this time [115]. MRP5 can transport purine nucleotide analogs [127] and is the primary active transporter of cGMP and cAMP [138]. Therefore MRP5 and -4 may work in concert to regulate cGMP and cAMP levels [127] in the brain. MRP6 can transport anionic organic ions but cannot transport glucuronide or GSH [127] and has been shown to transport leukotrinene C4 [139]. 6.6.6. MRP7, -8 and -9 Currently, little is known about these transporters with regards to the BBB. MRP7, -8 and -9 have been found to be expressed in brain [140]. MRP7 can transport glucuronide E2 17betaG and exhibits high levels of resistance to taxane docetaxel, approximately 9 to 13 fold [140]. MRP8 is able to transport nucleotide analogues such as PMEA, glutathione conjugates and methotrexate [140]. No substrates for MRP9 have been identified at this time [109]. When looking at drug resistant efflux transport in the literature, major focus has been put on P-gp and BCRP and limited research has been focused on members within the MRP subfamily as it relates to the BBB. As has been demonstrated here, many of these MRP transporters can transport substrates that are important both physiologically and in the clinic. Particularly within the CNS, it is important to decipher any discrepancies in location and expression of MRP members within the BBB because they can have relevant impact on CNS drug concen‐ trations reaching therapeutic levels within the brain and thus can affect our ability to treat important brain pathologies. 6.7. Breast Cancer Resistance Protein (BCRP) BCRP was originally discovered in the MCF-7 AdrVp breast cancer cell line after observing that the cells are resistant to chemotherapeutic drugs including mitoxantrone, doxorubicin, and daunorubicin [141]. The gene sequence of the protein was isolated shortly after and was classified as the group G subfamily of ABC transporters. There are at least 5 members of ABCG subfamily identified in humans (ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8). However, the primary form that plays a crucial role in the transport of substances between the blood and the CNS is ABCG2 [141]. At the protein level, ABCG2 is approximately 72-kDa with 665 amino acids and is considered as a half-transporter as shown in Figure 5. Other ABC transporters have two sets of membrane spanning regions (6 transmembrane α-helices) and two nucleotide binding domains (NBD); the G subfamily of protein consists of only one set of membrane spanning domain 6 transmembrane α-helices and only one NBD [141]. In order to function, it is believed that these half-transporters form homodimers [142]. The specific localization of ABCG2 within the CNS is primarily confined to the luminal plasma membrane of the brain microvessel endothelial cells. Given the localization within the BBB and the compounds that are transported by ABCG2, it has been suggested that ABCG2 most likely protects the brain from xenobiotics and toxins similar to other ABC transporters [141]. Furthermore, ABCG2 also plays a role in the accumulation and disposition of various endog‐ enous substrates including sulfate and glucuronide conjugates of estrone and dehydroepian‐ drosterone [143,144]. In addition to endogenous substrates, ABCG2 also binds and recognizes a broad range of structurally-unrelated drugs and xenobiotics [141]. Many of these transport substrates also interact with other ABC transporters including ABCB1 and the ABCC subfam‐ ily; thus, the accumulation and distribution of drugs can be significantly altered. 6.8. P-glycoprotein (P-gp) P-glycoprotein (P-gp) was the first ABC transporter to be characterized. First identified by Juliano and Ling [145] in 1976 using Chinese hamster ovary cells with selected resistance to colchicine, they discovered that the drug resistance properties of the mutated cells were consistently correlated with a high molecular weight component found in the plasma mem‐ brane with an approximate weight of 170,000 Da [145]. They also observed that the component was likely a glycoprotein associated with the plasma membrane of the mutated cells and was consistently absent or expressed at a lower level in the wild-type cells. Furthermore, they also noticed that the mutant cells with high levels of glycoprotein displayed an alter drug perme‐ ability; thus, they designated it as “P-glycoprotein” [145]. P-gp is also expressed in numerous tissues, including adrenal glands, kidneys, liver, colon, small intestine, heart, testes, peripheral nerves, and the brain. At the BBB, it is the most extensively studied ABC transporter being expressed in the luminal plasma membrane of brain endothelial cells [104]. Under normal conditions, the presence of P-gp in the BBB limits a broad range of substances from penetrating the brain tissue. Some notable drug classes with reduced brain penetration due to P-gp efflux at the BBB include anti-epileptics, anti-cancer drugs, anti-histamines and HIV protease inhibitors [103]. Numerous studies using drugs such as cyclosporine, digoxin, domperidone, etoposide, loperamide, ondansetron, taxol and vinblastine have shown the important role of P-gp in the pharmacokinetics of P-gp substrates in multiple parts of the body.
Structures-of-MRP-transporter-BCRP-transporter-and-P-glycoprotein-transporter

Structures of (A) MRP transporter, (B) BCRP transporter, and (C) P-glycoprotein transporter

Table 1 shows some of the drugs that are known substrates for P-gp. Similar to other ABC transporters, P-gp is a transmembrane protein with a molecular weight of 170 KDa formed by two homologous subunits that function as an efflux pump in an ATP-dependent manner (shown in Figure 5). The protein is assembled in two halves connected by a 75 amino acid linker region. Each half contains 6 transmembrane segments, an intracellular nucleotide binding domain, and both intracellular N and C terminal regions. The exact localization of P-gp had been a subject of some debate with evidence supporting both luminal and abluminal expression of the protein. Luminal P-gp expression had been observed in rat and mouse brain capillaries [115,146,147]. Furthermore, the luminal expression of P-gp has also been isolated in human brain microvessels [113,148]. In contrast, electron microscope techniques have shown an enhanced expression of P-gp on the abluminal side of the rat brain endothelial cells [149]. Nevertheless, recent studies using immunoreactivity support the localization of P-gp on the luminal side of the endothelial cells [116].
Representative compounds

Representative compounds that are known to be P-glycoprotein substrates

Numerous studies have attempted to identify and characterize P-gp substrates. Unlike conventional transporters, which recognize specific substrates, P-gp recognizes a broad range of compounds and has the capacity to extract its substrates directly from the plasma membrane [150]. Some of the most common features of P-gp substrates include their lipophilic nature that enables them to cross the lipid bilayer of the cell membrane. Furthermore, many P-gp sub‐ strates commonly consist of two aromatic rings and a basic nitrogen atom. These molecules can be uncharged or basic in nature, although some acidic compounds including methotrexate and phenytoin can also bind to P-gp but at a lower rate. Molecules with molecular weight ranges from 300 to 2000 Da are capable of binding to the protein and being transported [151]. Peptide substrates consisting of 3 to 15 amino acids with molecular weight ranges from 380 to 1880 Da can also interact with P-gp [151]. Most recently, beta amyloid protein, the component found in amyloid plaques in Alzheimer’s disease was reported to be a transport substrate of both P-gp but not BCRP [152,153]. One method for overcoming the limited permeability of P-gp transport substrates is to pharmacologically inhibit Pgp. P-glycoprotein inhibitors are themselves non-cytotoxic agents that can be used in combination with P-gp substrates to maintain the intracellular drug concentration. An inhibitor binds to P-gp and prevents the transport of P-gp substrates. There are at least three generations of P-gp inhibitors. The first generation compounds are less potent and non-selective with undesirable side effects at inhibitory concentrations. Examples of first generation inhibitors include the calcium channel blocker, verapamil, and the immunosup‐ pressive agent cyclosporin A. First generation P-gp inhibitors act as competitive inhibitors of P-gp transport [154]. The second-generation compounds including dexverapamil or dexniguldipine were devel‐ oped to reduce the toxicity associated with P-gp inhibition. They eliminate the undesirable side effects while retaining the ability to inhibit P-gp. The third generation inhibitors including tariquidar and elacridar are much more specific and more potent than earlier compounds. Unlike the first and second generation of P-gp inhibitors, the third generation of drugs acts as non-competitive inhibitors of P-gp, and the compounds themselves are not transported by P-gp [155]. Table 2 summarizes representative P-gp inhibitors [104].
Representative compounds

Representative compounds that are known to be P-glycoprotein inhibitors

The ability of P-gp to extrude xenobiotics provides protection and detoxification of cells under normal conditions. For example, knockout mice (MDR1a-/-) have been shown to be more sensitive to ivermectin and are susceptible to serious neurotoxicity compared to wild type control mice [156]. Considering the broad range of P-gp substrates and the expression of P-gp in tissues responsible for absorption, distribution and elimination of drugs, it is no surprise that this particular drug efflux transporter can significantly affect the absorption and distri‐ bution of drugs. This is especially true for cancer therapies used in the treatment of brain tumors. The tight junctions of the BBB restrict paracellular diffusion of chemotherapeutic agents into the CNS, while the presence of the various drug efflux transporters, such as P-gp, within the endothelial cells of the BBB reduces transcellular passage of chemotherapeutic agents into the brain and tumor sites. Conclusion The brain capillaries are structurally and functionally different from capillaries formed in the other organs. The selectiveness and permissiveness of the endothelial cell monolayer within the CNS is dependent on the tight junctions as wells as the numerous transporter systems located on the luminal and the abluminal surface of the endothelial cells forming the BBB. The restrictive nature of the tight junctions along with transporter systems expressed in the BBB can significantly altered the accumulation and distribution of fatty acids and drugs in the CNS under pathological conditions. Improved delivery to the brain can be achieved by reversibly disrupting the physical tight junctions and/or inhibiting the activity of efflux transporter systems. References [1] Rubin LL, Hall DE, Porter S, Barbu K, Cannon C, Horner HC, et al. A cell culture model of the blood-brain barrier. J Cell Biol 1991 Dec;115(6):1725-1735. [2] Gloor SM, Wachtel M, Bolliger MF, Ishihara H, Landmann R, Frei K. Molecular and cellular permeability control at the blood-brain barrier. Brain Res Brain Res Rev 2001 Oct;36(2-3):258-264. [3] Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and dis‐ ease. Pharmacol Rev 2005 Jun;57(2):173-185. [4] Kniesel U, Wolburg H. Tight junctions of the blood-brain barrier. Cell Mol Neurobiol 2000 Feb;20(1):57-76. [5] Mitchell RW, Edmundson CL, Miller DW, Hatch GM. On the mechanism of oleate transport across human brain microvessel endothelial cells. J Neurochem 2009 Aug; 110(3):1049-1057. [6] Mitchell RW, On NH, Del Bigio MR, Miller DW, Hatch GM. Fatty acid transport pro‐ tein expression in human brain and potential role in fatty acid transport across hu‐ man brain microvessel endothelial cells. J Neurochem 2011 May;117(4):735-746. [7] Urich E, Lazic SE, Molnos J, Wells I, Freskgård P. Transcriptional Profiling of Human Brain Endothelial Cells Reveals Key Properties Crucial for Predictive In Vitro Blood-Brain Barrier Models. PloS one 2012;7(5). [8] Huber JD, Egleton RD, Davis TP. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci 2001 Dec;24(12):719-725. [9] Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disor‐ ders. Neuron 2008 Jan 24;57(2):178-201. [10] Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006 Jan;7(1):41-53. [11] Haseloff RF, Blasig IE, Bauer HC, Bauer H. In search of the astrocytic factor(s) modu‐ lating blood-brain barrier functions in brain capillary endothelial cells in vitro. Cell Mol Neurobiol 2005 Feb;25(1):25-39. [12] Janzer RC, Raff MC. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature 1987 Jan 15-21;325(6101):253-257. [13] Balabanov R, Dore-Duffy P. Role of the CNS microvascular pericyte in the blood-brain barrier. J Neurosci Res 1998 Sep 15;53(6):637-644. [14] Lai CH, Kuo KH. The critical component to establish in vitro BBB model: Pericyte. Brain Res Brain Res Rev 2005 Dec 15;50(2):258-265. [15] Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 2004 Jun;16(1):1-13. [16] Matter K, Balda MS. Signalling to and from tight junctions. Nat Rev Mol Cell Biol 2003 Mar;4(3):225-236. [17] Morita K, Sasaki H, Furuse M, Tsukita S. Endothelial claudin: claudin-5/TMVCF con‐ stitutes tight junction strands in endothelial cells. J Cell Biol 1999 Oct 4;147(1): 185-194. [18] Sonoda N, Furuse M, Sasaki H, Yonemura S, Katahira J, Horiguchi Y, et al. Clostridi‐ um perfringens enterotoxin fragment removes specific claudins from tight junction strands: Evidence for direct involvement of claudins in tight junction barrier. J Cell Biol 1999 Oct 4;147(1):195-204. [19] Krause G, Winkler L, Mueller SL, Haseloff RF, Piontek J, Blasig IE. Structure and function of claudins. Biochim Biophys Acta 2008 Mar;1778(3):631-645. [20] Furuse M, Fujita K, Hiiragi T, Fujimoto K, Tsukita S. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occlu‐ din. J Cell Biol 1998 Jun 29;141(7):1539-1550. [21] Liebner S, Fischmann A, Rascher G, Duffner F, Grote EH, Kalbacher H, et al. Clau‐ din-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol 2000 Sep;100(3): 323-331. [22] Hirase T, Staddon JM, Saitou M, Ando-Akatsuka Y, Itoh M, Furuse M, et al. Occludin as a possible determinant of tight junction permeability in endothelial cells. J Cell Sci 1997 Jul;110 ( Pt 14)(Pt 14):1603-1613. [23] Feldman GJ, Mullin JM, Ryan MP. Occludin: structure, function and regulation. Adv Drug Deliv Rev 2005 Apr 25;57(6):883-917. [24] Aurrand-Lions M, Johnson-Leger C, Wong C, Du Pasquier L, Imhof BA. Heterogene‐ ity of endothelial junctions is reflected by differential expression and specific subcel‐ lular localization of the three JAM family members. Blood 2001 Dec 15;98(13): 3699-3707. [25] Mandell KJ, Parkos CA. The JAM family of proteins. Adv Drug Deliv Rev 2005 Apr 25;57(6):857-867. [26] Lippoldt A, Kniesel U, Liebner S, Kalbacher H, Kirsch T, Wolburg H, et al. Structural alterations of tight junctions are associated with loss of polarity in stroke-prone spon‐ taneously hypertensive rat blood-brain barrier endothelial cells. Brain Res 2000 Dec 8;885(2):251-261. [27] Gumbleton M, Audus KL. Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier. J Pharm Sci 2001 Nov; 90(11):1681-1698. [28] Miller D.W., Audus K.L. and Borchardt R.T. Application of cultured endothelial cells of the brain microvasculature in the study of the blood-brain barrier. J. Tiss. Cult. Meth 1992;14:217-224. [29] Trickler WJ, Mayhan WG, Miller DW. Brain microvessel endothelial cell responses to tumor necrosis factor-alpha involve a nuclear factor kappa B (NF-kappaB) signal transduction pathway. Brain Res 2005 Jun 28;1048(1-2):24-31. [30] de Vries HE, Blom-Roosemalen MC, de Boer AG, van Berkel TJ, Breimer DD, Kuiper J. Effect of endotoxin on permeability of bovine cerebral endothelial cell layers in vi‐ tro. J Pharmacol Exp Ther 1996 Jun;277(3):1418-1423. [31] Cecchelli R, Dehouck B, Descamps L, Fenart L, Buee-Scherrer VV, Duhem C, et al. In vitro model for evaluating drug transport across the blood-brain barrier. Adv Drug Deliv Rev 1999 Apr 5;36(2-3):165-178. [32] Abumrad N, Coburn C, Ibrahimi A. Membrane proteins implicated in long-chain fat‐ ty acid uptake by mammalian cells: CD36, FATP and FABPm. Biochim Biophys Acta 1999 Oct 18;1441(1):4-13. [33] Schaffer JE. Fatty acid transport: the roads taken. Am J Physiol Endocrinol Metab 2002 Feb;282(2):E239-46. [34] Brouns F, van der Vusse GJ. Utilization of lipids during exercise in human subjects: metabolic and dietary constraints. Br J Nutr 1998 Feb;79(2):117-128. [35] Pohl J, Ring A, Ehehalt R, Schulze-Bergkamen H, Schad A, Verkade P, et al. Long-chain fatty acid uptake into adipocytes depends on lipid raft function. Biochemistry 2004 Apr 13;43(14):4179-4187. [36] Drewes LR. What is the blood-brain barrier? A molecular perspective. Cerebral vas‐ cular biology. Adv Exp Med Biol 1999;474:111-122. [37] Kamp F, Hamilton JA, Kamp F, Westerhoff HV, Hamilton JA. Movement of fatty acids, fatty acid analogues, and bile acids across phospholipid bilayers. Biochemistry 1993 Oct 19;32(41):11074-11086. [38] Watkins PA, Hamilton JA, Leaf A, Spector AA, Moore SA, Anderson RE, et al. Brain uptake and utilization of fatty acids: applications to peroxisomal biogenesis diseases. J Mol Neurosci 2001 Apr-Jun;16(2-3):87-92; discussion 151-7. [39] Hamilton JA, Johnson RA, Corkey B, Kamp F. Fatty acid transport: the diffusion mechanism in model and biological membranes. J Mol Neurosci 2001 Apr-Jun; 16(2-3):99-108; discussion 151-7. [40] Hamilton JA, Guo W, Kamp F. Mechanism of cellular uptake of long-chain fatty acids: Do we need cellular proteins? Mol Cell Biochem 2002 Oct;239(1-2):17-23. [41] Abumrad N, Harmon C, Ibrahimi A. Membrane transport of long-chain fatty acids: evidence for a facilitated process. J Lipid Res 1998 Dec;39(12):2309-2318. [42] Schwenk RW, Holloway GP, Luiken JJ, Bonen A, Glatz JF. Fatty acid transport across the cell membrane: regulation by fatty acid transporters. Prostaglandins Leukot Es‐ sent Fatty Acids 2010 Apr-Jun;82(4-6):149-154. [43] Hamilton JA. Transport of fatty acids across membranes by the diffusion mechanism. Prostaglandins Leukot Essent Fatty Acids 1999 May-Jun;60(5-6):291-297. [44] Hamilton JA. Fatty acid transport: difficult or easy? J Lipid Res 1998 Mar;39(3): 467-481. [45] Frohnert BI, Bernlohr DA. Regulation of fatty acid transporters in mammalian cells. Prog Lipid Res 2000 Jan;39(1):83-107. [46] Hui TY, Bernlohr DA. Fatty acid transporters in animal cells. Front Biosci 1997 May 15;2:d222-31. [47] Storch J, Corsico B. The emerging functions and mechanisms of mammalian fatty acid-binding proteins. Annu Rev Nutr 2008;28:73-95. [48] Rapoport SI, Chang MC, Spector AA. Delivery and turnover of plasma-derived es‐ sential PUFAs in mammalian brain. J Lipid Res 2001 May;42(5):678-685. [49] Duncan RE, Bazinet RP. Brain arachidonic acid uptake and turnover: implications for signaling and bipolar disorder. Curr Opin Clin Nutr Metab Care 2010 Mar;13(2): 130-138. [50] Katsuki H, Okuda S. Arachidonic acid as a neurotoxic and neurotrophic substance. Prog Neurobiol 1995 Aug;46(6):607-636. [51] Chan PH, Fishman RA, Caronna J, Schmidley JW, Prioleau G, Lee J. Induction of brain edema following intracerebral injection of arachidonic acid. Ann Neurol 1983 Jun;13(6):625-632. [52] Chan PH, Fishman RA, Longar S, Chen S, Yu A. Cellular and molecular effects of polyunsaturated fatty acids in brain ischemia and injury. Prog Brain Res 1985;63:227-235. [53] Jaworowicz DJ,Jr, Korytko PJ, Singh Lakhman S, Boje KM. Nitric oxide and prosta‐ glandin E2 formation parallels blood-brain barrier disruption in an experimental rat model of bacterial meningitis. Brain Res Bull 1998 Aug;46(6):541-546. [54] Stanimirovic D, Satoh K. Inflammatory mediators of cerebral endothelium: a role in ischemic brain inflammation. Brain Pathol 2000 Jan;10(1):113-126. [55] Deli MA, Abraham CS, Kataoka Y, Niwa M. Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology. Cell Mol Neurobiol 2005 Feb;25(1):59-127. [56] Mark KS, Trickler WJ, Miller DW. Tumor necrosis factor-alpha induces cyclooxyge‐ nase-2 expression and prostaglandin release in brain microvessel endothelial cells. J Pharmacol Exp Ther 2001 Jun;297(3):1051-1058. [57] Jiang J, Quan Y, Ganesh T, Pouliot WA, Dudek FE, Dingledine R. Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation. Proc Natl Acad Sci U S A 2013 Feb 26;110(9):3591-3596. [58] Easton AS, Fraser PA. Arachidonic acid increases cerebral microvascular permeabili‐ ty by free radicals in single pial microvessels of the anaesthetized rat. J Physiol 1998 Mar 1;507 ( Pt 2)(Pt 2):541-547.
Next-> Neurology-NeuroChemistry Introduction